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Basal-supported oral therapy (BOT) is often used to treat poorly controlled type 2 
diabetes. However, patients sometimes experience nocturnal and early morning 
hypoglycemia. Thus, maintaining targeted glycemic control by BOT is limited in some 
patients. We assessed the efficacy and safety of replacing basal insulin by sitagliptin 
therapy in Japanese type 2 diabetes patients on BOT. Forty-nine subjects were 
sequentially recruited for the 52-week, prospective, single arm study. Patients on BOT 
therapy were switched from basal insulin to sitagliptin. The primary endpoint was 
change in HbA1c in 52-week. The secondary endpoints were dropout rate, changes in 
body weight, frequency of hypoglycemia, and relationship between change in HbA1c 
and insulin secretion capacity evaluated by glucagon loading test. The average dose of 
basal insulin was 15.0 ± 8.4 units. Sixteen subjects (31.3%) were dropped because 
replacement by sitagliptin was less effective for glycemic control. In these subjects, 
diabetes duration was longer, FPG and HbA1c at baseline were higher, and insulin 
secretion capacity was lower. Change in HbA1c in 52-week was -0.40% (95%CI -0.50 
to -0.32) (P<0.05). Change in body weight was -0.71 kg (95%CI -1.42 to -0.004) 
(P<0.05). Frequency of hypoglycemia was decreased from 1.21 ± 1.05 to 0.06 ± 0.24 
times/month. HbA1c level was improved if C-peptide index (CPI) was over 1.19. In 
conclusion, basal insulin in BOT can be replaced by sitagliptin with a decrease in 
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HbA1c level and frequency of hypoglycemia in cases where insulin secretion capacity 






Basal insulin preparation is recommended by the American Diabetes Association 
(ADA) / European Association for the Study of Diabetes (EASD) consensus algorithm 
when lifestyle interventions and oral glucose-lowering agents no longer achieve the 
glycemic goal of haemoglobin A1c (HbA1c) level less than 7% [1, 2]. Recently, two 
long-acting insulin analogues, insulin glargine and insulin detemir, are available that 
attain glycemic targets more effectively and safely [3, 4]. There are no significant 
differences reported in glycemic control and overall hypoglycemia between the two 
analogues [5]. The combination of basal insulin and oral hypoglycemic agents (OHAs), 
known as basal-supported oral therapy (BOT), is often used to treat poorly controlled 
type 2 diabetes [6, 7].
 
Better glycemic control, fewer hypoglycemic episodes, and less 
weight gain are obtained by BOT than by biphasic insulin [8]. In addition, BOT is 
relatively cost effective with the same glycemic control level as biphasic insulin 
regimen [9]. BOT is also helpful in Japanese type 2 diabetes patients. In the ALOHA 
(Add-on to Lantus® to OHA) study, in which 5,223 Japanese type 2 diabetes patents 
participated, mean HbA1c was reduced from 9.05 ± 1.15% to 7.63 ± 1.17% in 24-week 
[10]. Although BOT is well-tolerated and effective for glycemic control, patients 
sometimes experience nocturnal and early morning hypoglycemia. In the ALOHA study, 
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0.97% of the patients experienced frequent hypoglycemia.
 
In the 4T-study, 1.3% of 
BOT-treated patients experienced hypoglycemia with loss of consciousness [8]. 
Another problem of BOT is that postprandial glucose is high, although morning fasting 
blood glucose level is within normal range. An increase in dosage of basal insulin or 
SUs which are most commonly administrated in BOT-treated Japanese patients is not 
always effective, and can result in increased hypoglycemia. In Japanese interview forms, 
frequency of hypoglycemia induced by SUs is reported to be 1.3% to 2. 8%. Thus, 
maintaining targeted glycemic control by BOT is limited in some patients.  
Dipeptidyl peptidase-4 (DDP-4) inhibitor is a newly developed OHA that prevents 
degradation of the incretin hormones, glucagon-like peptide-1 and gastric inhibitory 
polypeptide [11]. This compound stimulates glucose-dependent insulin secretion and 
suppresses glucagon release, and can improve both fasting and postprandial glucose 
levels. Four different DPP-4 inhibitors are available in Japan: sitagliptin, vildagliptin, 
alogliptin, and linagliptin. Of these, sitagliptin is most widely used, partly because it 
was the first approved DPP-4 inhibitor and the safety and efficacy are acceptable in 
Japanese clinical practice. Generally, sitagliptin is more effective for glycemic control 
in Japanese patients compared to Caucasian patients [12, 13]. Sitaglipitn is usually 
combined with low dosage of SUs in Japan, less than or equal to 2 mg/day of 
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glimepiride and 40 mg/day of gliclazide, which is enough for glycemic control when 
combined with sitagliptin [14]. Patients also show improved glycemic control even if 
insulin secretion capacity is insufficient for oral therapy [14, 15]. The main 
pathophysiology of Japanese type 2 diabetes is impairment of insulin secretion [16, 17]. 
Insulin secretion capacity in Japanese populations is almost as half as that in Caucasians 
[18]. Especially, decreased basal and early phase insulin secretion is more contributed to 
Japanese type 2 diabetes [16]. Usually insulin therapy was needed in those whose 
C-peptide index (CPI) was lower than 0.8 [19]. However basal insulin therapy is not 
always ideal in some patients because postprandial glucose is still high, while 
preprandial glucose is low, resulting in large fluctuation in blood glucose. On the other 
hand, DPP-4 inhibitor could ameliorate decreased early phase insulin secretion. This 
encouraged us that basal insulin can be replaced with sitaglipitn in type 2 diabetes 
patients treated with SUs and basal insulin in some BOT cases.  
We show here that sitagliptin can be switched from basal insulin in patients with 
C-peptide index (CPI) and/or secretory unit of islet in transplantation (SUIT) equal to or 
larger than 1.19 and/or 36.4, respectively, with beneficial effects on glycemic control.   
 
MATERIALS AND METHODS 
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Study Design and Participants 
This was a prospective, 52-week, single center, single arm, intervention study to 
evaluate the effects on glycemic control of replacement of basal insulin to sitagliptin  
in type 2 diabetes patients inadequately controlled with BOT. Outpatients of Takashima 
General Hospital were recruited consecutively for a sample size of 45 subjects. 
Inclusion criteria were: type 2 diabetes treated with basal insulin (insulin glargine or 
detemir) and SUs (glimepiride or gliclazide) ± metformin ± thiazolidinedione ± 
-glucosidase inhibitors for more than 1 year; aged ≥ 20 years; HbA1c level ≥ 6.9%; no 
improvement in HbA1c ≥ 0.5% within 3 months in BOT; and a fasting C-peptide 
reactin (CPR) of > 0.5 ng/mL. Exclusion criteria were: type 1 diabetes; secondary 
diabetes; alcoholism; severe depression or severe psychological condition; malignancy; 
and abnormal hemoglobinemia. The study protocol was approved by the Institutional 
Review Board of Takashima General Hospital, and registered on University hospital 
Medical Information Network in Japan (UMIN000005499). Written informed consent 
was obtained from all subjects.  
 
Procedures and Intervention 
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The duration of the study was 52 weeks. Subjects were screened for eligibility and gave 
basic demographic information, medical history, and frequency of hypoglycemia. Within 
a month before changing therapy from basal insulin to sitagliptin, glucagon loading test 
was performed without any OHAs or basal insulin for more than 24 h to evaluate insulin 
secretion capacity. When basal insulin was replaced by sitagliptin, the dosage of 
glimepiride or gliclazide was decreased to equal to or less than 2.0 mg/day or 40 
mg/day, respectively, to prevent increased hypoglycemia if the subjects had been treated 
with more than 2.0 mg/day glimepiride or 40 mg/day gliclazide. If the subjects had been 
treated with equal to or less than 2.0 mg/day of glimepride or 40 mg/day of gliclazide, 
that dosage of SUs was maintained. Metformin (Met) and thiazolidinedione (TZD) were 
continued without any changes during the study. -glucosidase inhibitors were 
discontinued. The dosage of SUs was changed depending on the frequency of 
hypoglycemic episodes and glycemic control level. Sitagliptin was started at 50 mg/day, 
the usual initial dosage in Japan, which was increased to 100 mg/day if the HbA1c level 





The primary endpoint was change in HbA1c in 52-week. The secondary endpoints were 
dropout rate due to lesser efficacy of replacement by sitagliptin of basal insulin on 
glycemic control, change in body weight in 52-week, change in body mass index (BMI) 
in 52-week, change in frequency of hypoglycemia in 52-week, adverse events, and the 
correlation between change in HbA1c at 8-week and insulin secretion capacity or CPI or 
SUIT at baseline. HbA1c were expressed as NGSP values. CPI was calculated by the 
formula: [100 x fasting CPR (ng/mL)] / [18 x FPG (mM)] [19].
 
SUIT index was 
calculated by the formula: [250 x fasting CPR (nM)] / [(FPG-3.43) (mM)] [20]. Blood 
glucose and C-peptide level were measured before (0 min) and 6 min after intravenous 
administration of 1 mg glucagon.  
 
Statistical analysis 
Sample size was estimated to be 34 to detect a 0.4% change in HbA1c in 52-week with 
a power of 95%, alpha 0.05 two-tailed, beta 0.20, standardized effect size 0.7. To take 
the dropout rate of 30% into account, the aim was to include 45 subjects. IBM SPSS 
Statistics was used for analysis. Dependent samples Student’s t-test was used to 
compare the means of HbA1c level, insulin secretion capacity, BMI, body weight, age, 
and diabetes duration of the subjects between baseline and 52-week. Person’s 
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product-moment correlation test was used to evaluate the relationship between change 
in HbA1c and insulin secretion capacity or CPI or SUIT. To evaluate cut-off values of 
diabetes duration, FPG, HbA1c, 0-min CPR, 6-min CPR, delta-CPR, CPI, and SUIT, 
receiver operating characteristics curve (ROC) analysis was used. Independent samples 
Student’s t-test was used to compare the mean of change in HbA1c in 52-week between 
subjects treated with sitagliptin + glimepirde and sitagliptin + gliclazide. Dunnett 
analysis was used to compare change in HbA1c in 52-week among subjects treated with 
sitagliptin + SUs and sitagliptin + SUs + MET and sitagliptin + SUs + TZD. P values 




Forty-nine patients were eligible and were consecutively enrolled in the study (Table 1). 
Average age of subjects was 70.0 ± 10.2 years; ratio of male was 60.8%; duration of 
diabetes was 14.3 ± 8.2 years; average body weight was 62.3 ± 10.4 kg; average BMI 
was 24.3 ± 3.8 kg/m
2
; and HbA1c was 7.97 ± 0.81%. All subjects were treated with 
SUs; 17 subjects (34.7%) were treated with glimepiride (average dose 1.67 ± 1.47 mg) 
and 32 (65.3%) were treated with gliclazide (average dose 33.8 ± 12.0 mg). Average 
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dosage of basal insulin analogues was 15.0 ± 8.4 units. Glucagon loading test showed 
that 0-min CPR, 6-min CPR, CPI, and SUIT were 1.65 ± 1.02 ng/mL, 3.37 ± 1.98 
ng/mL, 1.19 ± 0.64, and 36.5 ± 22.1, respectively. Sixteen subjects (32.6%) were 
dropped due to an increase in HbA1c in 8-week; 6 (29.4%) and 11 (34.4%) were 
dropped in glimepiride- and gliclizaide-treated subjects, respectively (Table 2). No 
subjects were dropped for other reasons. Thirty-three subjects completed the study. 
 
HbA1c findings and dosage of SUs and sitagliptin 
Therapy adherence was confirmed by certified diabetes educators (nurses) in the study. 
Adherence of BOT therapy and the switching therapy were almost 100%, and there was 
no different between both therapies (Data not shown). 
HbA1c level in 52-week in final subjects was significantly decreased from 7.75 ± 
0.70% to 7.40 ± 0.68% (P<0.01) (Table 2). Change in HbA1c in 52-week was -0.40% 
(95%CI; -0.50, -0.32%) (P<0.05). HbA1c level in 52-week in glimepiride-treated 
subjects (n=12) was significantly decreased from 7.90 ± 0.85% to 7.16 ± 0.77% 
(P<0.01). Change in HbA1c in 52-week was -0.74% (95%CI; -1.03, -0.45%) (P<0.05). 
HbA1c level in 52-week in gliclazide-treated subjects (n=21) was significantly 
decreased from 7.66 ± 0.60% to 7.46 ± 0.61% (P<0.05). Change in HbA1c in 52-week 
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was -0.20% (95%CI; -0.35, -0.04%) (P<0.05). There was a significant difference in 
change in HbA1c in 52-week between glimepride-treated and gliclazide-treated subjects 
(P<0.01). The original dosages of glimepiride and gliclazide before the study were 1.58 
± 0.93 mg/day and 38.2 ± 14.0 mg/day, respectively; the initial dosages at the beginning 
of the study were significantly decreased to 0.96 ± 0.40 mg/day and 24.8 ± 8.7 mg/day, 
respectively (P<0.05); and the final dosages were significantly increased to 1.42 ± 0.57 
mg/day and 31.4 ± 12.0 mg/day, respectively, compared to the initial dosages (P<0.05), 
and were almost equal to the original dosages (Table 2). Final dosage of sitagliptin was 
74.2 ± 25.4 mg/day in all subjects; 70.8 ± 25.7 mg/day in glimepiride-treated subjects; 
and 77.3 ± 25.5 mg/day in gliclazide-treated subjects with no significant difference 
between the two groups.  
Of 33 subjects who completed the study, 22 subjects were treated with sitagliptin and 
SUs, 6 subjects were treated with sitagliptin and SUs and MET, and 3 subjects were 
treated with sitagliptin and SUs and TZD; changes in HbA1c in 52-week were -0.38% 
(95%CI; -0.58, -0.19%) (P<0.05), -0.54% (95%CI; -0.90, -0.20%) (P<0.05), and 
-0.23% (95%CI; -0.43, -0.04%) (P<0.05), respectively (Table 2). However, there was 




Change in body weight, BMI, and frequency of hypoglycemia 
Body weight in final subjects at baseline was 64.2 ± 9.5 kg, and was decreased to 63.5 ± 
8.7 kg at 52-week. Change in body weight in 52-week was -0.71 kg (95%CI; -1.42, 
-0.004 kg) (P<0.05) (Table 3). BMI at baseline was 24.8 ± 3.6 kg/m
2
, and decreased to 
24.5 ± 3.4 kg/m
2





) (P>0.05).  
Frequency of hypoglycemia at baseline was 1.21 ± 1.05 times/month, and was 
significantly decreased to 0.06 ± 0.24 times/month at 52-week (P<0.001). Change in 
frequency in hypoglycemia in 52-week was -1.21 times/months (95%CI; -1.5, -0.80) 
(P<0.05) (Table 3). During the study, no severe hypoglycemia was noted.  
During the study, no other adverse events were not observed after replacement of basal 
insulin with sitagliptin.  
 
Differences in HbA1c findings in 8-week in the final and dropped subjects  
Sixteen subjects of 49 recruited were dropped after 8-week due to increased HbA1c 
level. The remaining 33 subjects completed the study. HbA1c level at baseline (0-week) 
in final subjects was 7.75 ± 0.70%, and was significantly decreased to 7.45 ± 0.61% at 
8-week (P<0.001) (Table 4). Change in HbA1c was -0.32% (95%CI; -0.45, -0.20%) 
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(P<0.05). On the other hand, HbA1c level at baseline (0-week) in dropped subjects was 
significantly higher than that in final subjects (P<0.05), and was significantly increased 
from 8.42 ± 0.87% to 8.86 ± 0.99% in 8-week (P<0.01). Change in HbA1c was +0.64% 
(95%CI; 0.29, 1.00%) (P<0.05).  
 
Differences in clinical factors in final and dropped subjects  
There were no differences in age, sex, dosage of SUs, or dosage of basal insulin in final 
and dropped subjects (Table 4). Body weight and BMI also were not significantly 
different (P=0.065 and P=0.2432, respectively). On the other hand, diabetes duration in 
dropped subjects was longer than that in final subjects (12.1 ± 6.6 vs. 18.7 ± 9.5 years, 
P<0.05). FPG and HbA1c also were higher in dropped subjects than in final subjects 
(FPG; 7.4 ± 1.5 vs. 8.9 ± 2.9 mM, P<0.05) (HbA1c; 7.75 ± 0.70 vs. 8.42 ± 0.87%, 
P<0.01).   
Insulin secretion capacity was significantly higher in final subjects than that in dropped 
subjects (Table 4) (P<0.05). In final subjects, CPR level at 0-min, 6-min, and delta CPR 
(6-min CPR – 0-min CPR) were 1.95 ± 1.25 ng/mL, 3.81 ± 2.13 ng/mL, and 1.98 ± 1.35 
ng/mL, respectively. In dropped subjects, CPR level at 0-min, 6-min, and delta CPR 
were 1.37 ± 0.64 ng/mL, 2.42 ± 1.21 ng/mL, and 1.16 ± 0.69 ng/mL, respectively. CPI 
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and SUIT index also were significantly higher in final subjects than those in dropped 
subjects. CPI at baseline in final subjects was 1.35 ± 0.68, while that in dropped 
subjects was 0.92 ± 0.51 (P<0.05). SUIT at baseline was 42.7 ± 23.0 in final subjects, 
and 23.1 ± 10.6 in dropped subjects (P<0.01). We examined cut-off values of diabetes 
duration, FPG, HbA1c, 0-min CPR, 6-min CPR, delta-CPR, CPI, and SUIT by 
analyzing ROC curves; they were 16.5 years, 8.2 mM, 7.8%, 1.25 ng/ml, 2.80 ng/ml, 
1.60 ng/ml, 1.34, and 37.5, respectively (Fig. 1).This indicates that with longer diabetes 
duration, insulin secretion capacity becomes lower and the consequent poorer glycemic 
control makes switching BOT-treated patients from basal insulin to sitagliptin unsafe.  
 
Correlation between efficacy of sitagliptin on glycemic control and insulin 
secretion capacity, CPI, and SUIT 
We examined whether or not insulin secretion capacity, CPI, or SUIT at baseline 
predicted the efficacy of replacing basal insulin with sitagliptin on glycemic control 
(Fig. 2). There was a correlation between change in HbA1c at 8-week and 0-min CPR 
(r=-0.281), 6-min CPR (r=-0.326), and delta CPR (r=-0.290), assessed by glucagon 
loading test at baseline (Fig. 2A, B, C) (P<0.05). In addition, CPI (r=-0.360) or SUIT 
(r=-0.306) at baseline was correlated with change in HbA1c at 8-week (Fig. 2D, E) 
16 
 
(P<0.05). The value of 0-min CPR, 6-min CPR, delta CPR, CPI, and SUIT at which the 
HbA1c level was not increased by replacement of basal insulin by sitagliptin were 
calculated to be 1.64 ng/mL, 3.36 ng/mL, 1.71 ng/mL, 1.19, and 36.4, respectively, by 
Pearson’s product-moment correlation test (Table 5). The value of 0-min CPR, 6-min 
CPR, delta CPR, CPI, and SUIT at which the HbA1c level was decreased by 0.5% in 
8-week were calculated to be 1.86 ng/mL, 3.83 ng/mL, 1.98 ng/mL, 1.36, and 41.3, 
respectively. Other clinical characteristics of the patients such as disease duration and 
body weight were not significantly correlated with efficacy of replacing basal insulin 




We show here that basal insulin can be switched to sitagliptin with good effects in type 
2 diabetes patients treated with BOT. With this treatment, the HbA1c level decreased 
from 7.75 ± 0.70% to 7.35 ± 0.68% in 52-week (P<0.01). The change in HbA1c in 
52-week was -0.40% (95%CI; -0.50, -0.32) (P<0.05). The efficacy of switching to 
sitagliptin from basal insulin was correlated with insulin secretion capacity, CPI, and 
SUIT, CPI being most correlated marker in the present study. The average CPI in final 
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subjects was 1.35 ± 0.68 ng/mL, while that of dropped subjects was 0.92 ± 0.51 ng/mL. 
Pearson’s product-moment correlation test revealed that HbA1c was improved by 
switching from basal insulin to sitagliptin if CPI was equal to or higher than 1.19 (Fig. 
2D and Table 5). Similarly, basal insulin could be switched to sitagliptin if SUIT was 
equal to or larger than 36.4 (Fig. 2E and Table 5). In the dropped subjects, diabetes 
duration was longer, FPG and HbA1c were worse, 0-min CPR, 6-min CPR, delta-CPR, 
CPI, and SUIT were lower compared to those in final subjects. (Table 4). Cut-off values 
of them were 16.5 years, 8.2 mM, 7.8%, 1.25 ng/ml, 2.80 ng/ml, 1.60 ng/ml, 1.34, and 
37.5, respectively (Fig. 1). This suggests that the efficacy of switching from basal 
insulin to sitagliptin, when combined with SUs, is dependent on basal glycemic control 
and the insulin secretion capacity. Baseline HbA1c of dropped subjects was higher than 
that of the final subjects. Dosage of basal insulin was more required to reach target 
HbA1c level in dropped subjects compared to that in the final subjects because of lower 
insulin secretion capacity. Thus, if baseline HbA1c level had been reduced by 
increasing dosage of basal insulin, it would be difficult to replace basal insulin to 
sitagliptin. 
Replacement of basal insulin by sitagliptin resulted in a reduction in body weight and 
hypoglycemia. Body weight was reduced by 0.71 kg (95%CI; -1.41 to -0.004 kg) 
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(P<0.05). Frequency of hypoglycemia was decreased from 1.21 ± 1.05 to 0.06 ± 0.24 
times/month (P<0.001). Since sitagliptin is known to be body weight neutral [21, 22], 
discontinuation of basal insulin might contribute to body weight reduction. The 
combination of basal insulin and SUs often induces mild hypoglycemia by which 
patients feel a sense of hunger and eat between-meal snacks. This sometimes induces 
weight gain and poor glycemic control in BOT-treated patients. On the other hand, 
combination therapy with sitagliptin and low dosage SUs (less than or equal to 2 
mg/day glimepiride or 40 mg/day gliclazide) was body weight neutral or led a decrease 
in BMI [14]. In the current study, hypoglycemia seldom occurred, and BMI was 
significantly decreased by 0.38 kg/m
2
 (95%CI -0.72 to -0.04 kg/m
2
) [14]. Switching 
from basal insulin to sitagliptin also reduced the frequency of hypoglycemia. Although 
energy intake was not evaluated between baseline and 52-week in the present study, 
patients who had previously experienced frequent hypoglycemia reported to their 
physicians that the number of between-meal snacks in 52-week was fewer than at 
baseline. Thus, excess energy intake may be reduced after switching from basal insulin 
to sitagliptin to account for some of the body weight reduction and improvement in 
HbA1c. Another reason for improvement in the HbA1c level may be the reduced 
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postprandial glucose level by the combination therapy with sitagliptin and SUs 
compared to that by BOT.  
The combination therapy of glimepiride and sitagliptin was more effective for HbA1c 
reduction than that of gliclazide and sitagliptin. Recently, it was reported that cAMP 
sensor Epac2 is a direct target of several sulfonylureas [23]. Tolbutamide, glibenclimide, 
and glimepiride bound Epac2 and enhanced glucose-stimulated insulin secretion. 
However, gliclazide did not bind Epac2. Because Epac2 also mediates the potentiation 
of insulin secretion by cAMP increased by endogenous incretin, the combination 
therapy of glimepiride and sitagliptin more enhances insulin secretion through 
activation of Epac2. This might be a potential mechanism why the combination therapy 
of glimepiride and sitagliptin was more effective for glycemic control than that of 
gliclazide and sitagliptin.  
Generally, insulin secretion capacity of Japanese is as half as that of Caucasian [16, 17, 
18]. Therefore, more than 60% of Japanese type 2 diabetes patients are treated with SUs 
[24]. DPP-4 inhibitor now is one of the most popular OADs, and more than 2 million 
patients were treated with DPP-4 inhibitors in Japan. Based on pathophysiology of 
Japanese patients and the mechanism of incretin effect, the combination therapy with SUs 
and DPP-4 inhibitors seems to be most effective for glycemic control compared to that 
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with other OADs and DPP-4 inhibitors. On the other hand, the main pathophysiology of 
Caucasian type 2 diabetes is insulin resistance compared to that of Japanese type 2 
diabetes [25, 26]. Dosage of basal insulin in BOT in Caucasian patients is greater than 
that in Japanese patients. For example, in 4-T study, the mean dosage of basal insulin 
was 86 U (1.03 U/kg) [8], while 8.5 U (0.15 U/kg) in Japanese type 2 diabetes [10], and 
15 U (0.24 U/kg) in our study. Therefore, it is not sure if basal insulin could be replaced 
with DPP-4 inhibitors even in subjects treated with high dosage of basal insulin. 
However, there is still possibility that in Caucasian subjects whose BMI is less than 25 
kg/m
2
 and CPI is over 1.3, basal insulin could be replaced with DPP-4 inhibitors. Or, if 
the combination therapy with high dosage of MET and DPP-4 inhibitors is more effective 
for glycemic control compared to other combinations in Caucasian type 2 diabetes, basal 
insulin with MET could be replaced with DPP-4 inhibitors and metformin.     
During the course of the disease, type 2 diabetes patients are treated with several OHAs 
[27, 28]. However, if the HbA1c level does not reach less than 7%, insulin treatment is 
considered the next step [1, 2]. BOT is often selected for outpatients because once daily 
injection is acceptable and the glycemic control is superior, with fewer hypoglycemic 
episodes and less weight gain compared to biphasic insulin [8]. In Japan, the commonly 
used SUs are combined with basal insulin in BOT [10]. One of the biggest problems of 
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combination therapy with basal insulin and SUs is the high level of postprandial blood 
glucose while fasting blood glucose is within normal range. An increase in dosage of 
SUs or basal insulin does not resolve this problem, and sometimes leads to increased 
hypoglycemia. However, our results show that better glycemic control and lower 
frequency of hypoglycemia is obtained when switching from basal insulin to sitagliptin 
in subjects with sufficiently preserved insulin secretion capacity.  
The advantages of discontinuation of basal insulin are 1) patients become free from 
daily injections; 2) they do not need to regularly perform self-monitoring of blood 
glucose (SMBG); and 3) oral therapy costs less than insulin therapy.  
In summary, basal insulin in BOT can be switched to sitagliptin if CPI and/or SUIT are 
equal to or higher than 1.19 or 36.4, respectively. On the other hand, sitagliptin can be 
added to insulin therapy if insulin secretion capacity is not sufficient for switching to 
sitagliptin. However, the effectiveness of combination therapy with basal insulin and 
sitagliptin on glycemic control in type 2 patients with CPI and/or SUIT less than 1.19 or 
36.4, respectively, is unknown. Further studies are required to determine the optimum 
insulin secretion capacities for switching BOT therapy to sitagliptin combined with SUs 
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Fig. 1 Cut-off values and receiver-operator characteristic curves of (a) diabetes duration, 
(b) fasting plasma glucose, (c) HbA1c, (d) 0-min CPR, (e) 6-min CPR, (f) delta CPR, 
(g) CPI, and (h) SUIT at baseline. CPR, C-peptide reaction; CPI, C-peptide index; SUIT, 
the secretory unit of islet in transplantation.  
 
Fig. 2 Relationship between change in HbA1c in 8-week and results of glucagon 
loading test, CPI, and SUIT at baseline. Change in HbA1c in 8-week and 0-min CPR (a), 
6-min CPR (b), delta CPR (c), CPI (d), and SUIT index (e) at baseline. CPR, C-peptide 





Table 1 Demographic and clinical features of subjects participating in the 
study 
Subjects (n) 49 Basal insulin 15.0 ± 8.4 units 
Age (years) 70.0 ± 10.2 Medications  SU  100 % 
Glimepiride   34.7% 
          1.67 ± 1.47mg 
Gliclazide   65.3%     




14.3 ± 8.2 
Metformin  22.4%   
           636 ± 131mg 
Complications Nephropathy 
61.2% 
Thiazolidinedione  16.3% 
           10.3 ± 3.9mg 
Retinopathy 
69.4% 
a-glucosidase inhibitors     




0-min CPR (ng/mL) 
 
1.65 ± 1.02 
Cardiovascular 
diseases  34.7% 
  6-min CPR (ng/mL) 3.37 ± 1.98 
Weight (kg) 62.3 ± 10.4   Delta CPR (ng/mL) 1.72 ± 1.23 
BMI (kg/m2) 24.3±3.8 CPI 1.19 ± 0.64 
HbA1c (%) 7.97±0.81 SUIT 36.5 ± 22.1 
 

















dosage of SUs 
(mg) 
Initial dosage 
of SUs (mg) 
Final dosage  








7.75 ± 0.70 7.35 ± 0.68** 
-0.40%* 
(-0.50, -0.32%) 





7.90 ± 0.85 7.16 ± 0.77** 
-0.74%* 
(-1.03, -0.45%) 





7.66 ± 0.60 7.46 ± 0.61* 
-0.20%* 
(-0.35, -0.04%) 





7.63 ± 0.67 7.26 ± 0.68* 
-0.38%* 
(-0.58, -0.19%) 
- - - 67.4 ± 24.3 




7.99 ± 0.80 7.43 ± 0.72 
-0.54%* 
(-0.90, -0.20%) 
- - - 87.5 ± 23.1 




8.10 ± 0.56 7.87 ± 0.40 
-0.23%* 
(-0.43, -0.04%) 
- - - 100 ± 0.0 
*P<0.05 
              **P<0.01 









0-week 64.2 ± 9.5 24.8 ± 3.6 1.21 ± 1.05 









      *P<0.05 
      ***P<0.001 










0 Wk HbA1c (%) 7.75 ± 0.70 8.42 ± 0.87 
Original dosage  
of SUs (mg) 
Glimepiride 
1.58 ± 0.93 
Gliclazide 
36.2 ± 10.2 
Glimepiride 
2.70 ± 2.05 
Gliclazide 
38.2 ± 14.1 
8 Wk HbA1c (%) 7.45 ± 0.61*** 8.86 ± 0.99** Basal insulin (Units) 14.8 ± 9.3 15.2 ± 6.4 






FPG (mM) 7.4 ± 1.5 8.9 ± 2.9* 
Age (years) 69.8 ± 10.7 70.5 ± 9.3 HbA1c (%) 7.75 ± 0.70 8.42 ± 0.87** 
Male (%) 66.7 56.3 
Glucagon test 
0-min CPR (ng/mL) 
1.95 ± 1.25 1.37 ± 0.64* 
Diabetes 
duration (years) 
12.1 ± 6.6 18.7 ± 9.5* 6-min CPR (ng/mL) 3.81 ± 2.13 2.42 ± 1.21* 
Weight (kg) 64.2 ± 9.5 58.4 ± 11.5 Delta CPR (ng/mL) 1.98 ± 1.35 1.16 ± 0.69* 
BMI (kg/m2) 24.8 ± 3.6 23.4 ± 4.0 CPI 1.35 ± 0.68 0.92 ± 0.51* 
   SUIT 42.7±23.0 23.1±10.6** 
         *P<0.05 **P<0.01 ***P<0.001 











0 .0 1.64 3.36 1.71 1.19 36.4 
-0.5 1.86 3.83 1.98 1.36 41.3 
            
 
















Cut-off value 16.5 8.2 7.8 1.25 2.80 1.60 1.34 37.5 
            
 
 
